TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14756429
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (6 cycles of CEF after primary surgery)
Study: 28816026
Drug: 2000-mg sustained-release
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000-mg sustained-release (SR) acetaminophen
Study: 28816026
Drug: 1500-mg sustained-release
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500-mg sustained-release (SR) acetaminophen
Study: 22949381
Drug: Hair zinc
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hair zinc levels in RW group (162.43 ± 91.52 µg/g)
Study: 22949381
Drug: Hair selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hair selenium levels in RW group (217.37 ± 83.01 µg/g)
Study: 22949381
Drug: Total antioxidant
Normalized name: Ascorbic Acid/Coenzyme Q10/Grape Seed Extract/Green Tea Extract/Lutein/Lycopene/Selenium/Thioctic Acid/Tocotrienol/Turmeric Extract/Vitamin A/Vitamin E 60 MG-5 MG-10 MG-10 MG-3 MG-1.5 MG-0.1 MG-7.5 MG-5 MG-15 MG-5000 IU-75 IU Oral Capsule, Liquid Filled [TOTAL ANTIOXIDANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total antioxidant capacity (TAC) in RW group (1.38 ± 0.14 mmol/L)
Study: 21090334
Drug: Medication (metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (metformin 250 mg t.i.d. for 1 week, then 500 mg t.i.d. for 6 months)
Study: 21090334
Drug: Medication (metformin)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (metformin)
Study: 18661264
Drug: 0.5% levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levofloxacin (LVFX) ophthalmic solution applied for 3 days with diluted PI eyewash
Study: 18661264
Drug: 0.5% levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levofloxacin (LVFX) ophthalmic solution applied for 1 day with diluted PI eyewash
Study: 18661264
Drug: 0.5% levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levofloxacin (LVFX) ophthalmic solution applied for 1 hour with diluted PI eyewash
Study: 15897530
Drug: Rifaximin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (200 mg/d, 200 mg twice daily, or 200 mg 3 times daily)
Study: 10818278
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg ipsapirone
Study: 6635439
Drug: Parenteral nafcillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nafcillin plus oral rifampin
Study: 6635439
Drug: Parenteral nafcillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nafcillin alone
Study: 6635439
Drug: Rifampin in
Normalized name: rifampin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin in combination with other oral antibiotics
Study: 30569662
Drug: Sanhuang Xiexin
Normalized name: MENTHOL 4.3 g / METHYL SALICYLATE 9.4 g TOPICAL OIL [Shuang Long Pain Relieving Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanhuang Xiexin decoction + basic treatment (SX group)
Study: 30569662
Drug: basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: basic treatment (control group)
Study: 28650204
Drug: XEN-D0501 (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN-D0501 (oral, 4 mg twice daily)
Study: 25905795
Drug: Meningococcal B
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal B outer membrane vesicle vaccine
Study: 19767576
Drug: Tannic acid
Normalized name: Tannic Acid
DrugBank: Tannic acid (DB09372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tannic acid (TA) treatment (10% and 20%)
Study: 19767576
Drug: Tannic acid
Normalized name: Tannic Acid
DrugBank: Tannic acid (DB09372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tannic acid (TA) treatment
Study: 1828204
Drug: Thymopentin (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (continued treatment during phase II)
Study: 19852289
Drug: Metformin (WM1)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (WM1)
Study: 17885221
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with early motion controlled in a removable orthosis, progressing to full weightbearing at 8 weeks.
Study: 17885221
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment with early motion controlled in a removable orthosis, progressing to full weightbearing at 8 weeks.
Study: 16366764
Drug: Lorazepam (1.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1.0, 2.0 mg/70 kg, oral)
Study: 16366764
Drug: Scopolamine (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.3, 0.6 mg/70 kg, subcutaneous)
Study: 11898005
Drug: 0.1% hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% hydrocortisone butyrate ointment
Study: 7297433
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of magaldrate administered every two hours
Study: 7297433
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of magaldrate administered every three hours
Study: 31050949
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + Laser (SRP + L)
Study: 19631773
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no low-intensity pulsed ultrasound treatment)
Study: 16344342
Drug: Azathioprine, up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine, up to 3 mg/kg daily, individually adjusted according to blood lymphocyte number and the occurrence of adverse events.
Study: 9585822
Drug: Ebastine tablets
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine tablets
Study: 7707108
Drug: CMFVP (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMFVP (1 year of therapy with continuous cyclophosphamide, methotrexate, fluorouracil (5‐FU), vincristine, and prednisone)
Study: 7707108
Drug: FAC-M (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC-M (20 weeks of therapy with four 5‐week courses of treatment with 5‐FU, doxorubicin, cyclophosphamide, and methotrexate)
Study: 58143
Drug: B.C.G. plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: B.C.G. plus 5-fluorouracil (5-F.U.)
Study: 58143
Drug: B.C.G. alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: B.C.G. alone
Study: 27088271
Drug: Kinesio taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio taping plus paracetamol
Study: 27088271
Drug: Paracetamol (control)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (control)
Study: 12125505
Drug: Furosemide +
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide + albuterol (1 and 0.15 mg/kg, respectively)
Study: 12125505
Drug: Albuterol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (0.15 mg/kg)
Study: 26658119
Drug: Colostrum administration
Normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colostrum administration every 2 h for 46 h
Study: 24884888
Drug: Internet-based cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioural therapy (8 modules delivered online)
Study: 20386309
Drug: Plasma interleukin‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma interleukin‐8 levels > or =220 pg/mL
Study: 20386309
Drug: Plasma interleukin‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma interleukin‐8 cutoff <220 pg/mL
Study: 20386309
Drug: Plasma interleukin‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma interleukin‐8 cutoff <220 pg/mL in adults aged <40 yrs
Study: 15974218
Drug: Bleaching gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching gel with added amorphous calcium phosphate (ACP)
Study: 12675869
Drug: Serial slow-flow
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial slow-flow pressure (SFpr = OP/MABP at Qb of 50 mL/min)
Study: 8908436
Drug: Norfloxacin ophthalmic
Normalized name: norfloxacin ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin ophthalmic solution 0.3%
Study: 1827418
Drug: 0.020 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.020 mg ethynilestradiol + 0.150 mg desogestrel (Mercilon)
Study: 1827418
Drug: 0.030 mg
Normalized name: LEVONORGESTREL 0.050 mg / ETHINYL ESTRADIOL 0.030 mg ORAL TABLET, COATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.030 mg ethynilestradiol + 0.150 mg desogestrel (Marvelon)
Study: 1827418
Drug: 0.020 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.020 mg ethynilestradiol (Mercilon)
Study: 1827418
Drug: 0.030 mg
Normalized name: LEVONORGESTREL 0.050 mg / ETHINYL ESTRADIOL 0.030 mg ORAL TABLET, COATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.030 mg ethynilestradiol (Marvelon)
Study: 6345174
Drug: Intermittent high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent high-dose melphalan/prednisone (MP)
Study: 6345174
Drug: Continuous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous low-dose melphalan (M)
Study: 30608426
Drug: aPDT (antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: aPDT (antimicrobial photodynamic therapy)
Study: 17605095
Drug: AF Suppression
Normalized name: Canesten AF
Approvals — FDA: no, EMA: no, PMDA: no
Description: AF Suppression algorithm ON (treatment group)
Study: 9719037
Drug: Sugar-free, urea-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-free, urea-containing chewing gum (20 mg urea/piece), 5 pieces/day
Study: 26386786
Drug: Varenicline (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (1.0 mg twice daily)
Study: 17211114
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no exercise treatment during the research period)
Study: 12899796
Drug: Suppository treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository treatment for bleeding due to hemorrhoid
Study: 12899796
Drug: Suppository treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository treatment for prolapse of hemorrhoid
Study: 1310497
Drug: etanidazole (ETA)
Normalized name: Tinidazole
DrugBank: Etanidazole (DB12736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: etanidazole (ETA) unmodified (2 g/m2, 3 times weekly for 17 doses)
Study: 1310497
Drug: etanidazole (ETA)
Normalized name: Tinidazole
DrugBank: Etanidazole (DB12736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: etanidazole (ETA) individualized dose modification
Study: 29018084
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (0.5 mg/kg)
Study: 20940337
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin (5 U)
Study: 20940337
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (10 U)
Study: 20940337
Drug: Inhaled Technosphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Technosphere insulin (25, 50, and 100 U)
Study: 15118650
Drug: Prenatal zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal zinc supplementation (25 mg zinc)
Study: 7884791
Drug: Moexipril monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril monotherapy (7.5, 15, or 30 mg once daily)
Study: 7884791
Drug: Moexipril combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril combined with hydrochlorothiazide (15-30 mg daily with 12.5 mg hydrochlorothiazide)
Study: 30706520
Drug: Active strategy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active strategy for the diagnosis and anticoagulant treatment of pulmonary embolism (PE)
Study: 30706520
Drug: Active strategy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active strategy for the diagnosis and anticoagulant treatment of PE
Study: 18000659
Drug: Erlotinib with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib with ketoconazole (CYP3A4 inhibitor)
Study: 17010056
Drug: Selective estrogen
Normalized name: Selective estrogen receptor modulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective estrogen receptor modifiers (tamoxifen, raloxifene)
Study: 11128246
Drug: Gabapentin monotherapy
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin monotherapy after discontinuation of carbamazepine (CBZ)
Study: 11128246
Drug: Other antiepileptic
Normalized name: Other antiepileptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antiepileptic medications
Study: 1493661
Drug: Propionyl-L-carnitine (PLC)
Normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine (PLC) 1 g b.i.d
Study: 2859304
Drug: Rapidly eliminated
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rapidly eliminated hypnotics (triazolam, midazolam, lormetazepam)
Study: 2859304
Drug: Slowly eliminated
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slowly eliminated hypnotics (flurazepam, quazepam)
Study: 24472084
Drug: Compound betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compound betamethasone 7 mg intramuscular injection (i.m.) once
Study: 24472084
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 75 mg twice a day for 7 days
Study: 17907112
Drug: No GIK
Approvals — FDA: no, EMA: no, PMDA: no
Description: No GIK infusion (Control)
Study: 2025478
Drug: Ketanserin 10
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 10 mg i.v. followed by an infusion of 0.075 mg kg‐1 h‐1
Study: 6894644
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (20 minutes of isometric exercises)
Study: 30257898
Drug: Ceftaroline disk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftaroline disk diffusion with 30-μg disks
Study: 30257898
Drug: Ceftaroline MIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftaroline MIC of 2 μg/ml
Study: 30257898
Drug: Ceftaroline MIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftaroline MIC of 1 μg/ml
Study: 30257898
Drug: Ceftaroline MIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftaroline MIC of ≥4 μg/ml
Study: 25729196
Drug: Spinal decompression
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal decompression therapy (SDTG, n=15)
Study: 25729196
Drug: General traction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: General traction therapy (GTTG, n=15)
Study: 18679072
Drug: PEG‐IFN monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN monotherapy (n=64)
Study: 16531440
Drug: tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tranexamic acid 10 mg kg(‐1) i.v. just before tourniquet deflation and 3 h later
Study: 16531440
Drug: epsilon‐aminocaproic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: epsilon‐aminocaproic acid 100 mg kg(‐1) before tourniquet deflation followed by continuous perfusion (1 g h(‐1)) during 3 h
Study: 11966791
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg twice a day for 10 days
Study: 11966791
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg twice a day for 14 days
Study: 162923
Drug: Adenine arabinoside
Normalized name: Adenine
DrugBank: Adenine (DB00173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenine arabinoside (20 mg/kg of body weight, intravenously every 24 hr for seven days in an 8-hr infusion)
Study: 7362724
Drug: Suxamethonium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 1.0 mg kg‐1
Study: 26867157
Drug: Panitumumab added
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab added to docetaxel-based chemotherapy
Study: 26867157
Drug: Docetaxel-based chemotherapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel-based chemotherapy alone
Study: 17992451
Drug: UVB monotherapy
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UVB monotherapy
Study: 12010156
Drug: Non-submerged ITI
Normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-submerged ITI implants
Study: 12010156
Drug: First 498
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First 498 implants after at least five years of functional loading
Study: 12010156
Drug: 12 mm
Normalized name: ReliOn Pen Needle 29g 12 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mm long implants
Study: 12010156
Drug: 8 mm
Normalized name: potassium 8 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mm long implants
Study: 12010156
Drug: Implants supporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants supporting maxillary overdentures retained by Dolder bars
Study: 7821124
Drug: Loxiglumide (CCK-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (CCK-receptor antagonist)
Study: 1695053
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMW heparin) given once daily
Study: 76748
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (E.C.T.)
Study: 20037706
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone hexacetonide combined with 15 mCi Samarium(153)‐particulate hydroxyapatite (Sm/TH group)
Study: 20037706
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone hexacetonide alone (TH group)
Study: 17696821
Drug: Biologic drugs
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic drugs
Study: 15151687
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education programme (yearly 1-h instruction)
Study: 12359855
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid at 4 mg
Study: 12359855
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid at 8/4 mg
Study: 12359855
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid at 4 mg and 8/4 mg
Study: 1155918
Drug: Gentamicin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (2 mg/kg)
Study: 26265109
Drug: Warming blanket
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming blanket plus prewarmed intravenous (i.v.) infusion
Study: 20189775
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg every 12h for 5 days
Study: 20189775
Drug: Oseltamivir 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 225 mg every 12h for 5 days
Study: 20189775
Drug: Oseltamivir 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 450 mg every 12h for 5 days
Study: 10812285
Drug: THC (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (0 mg)
Study: 8684686
Drug: r-HuEPO (4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-HuEPO (4000 IU/ml, subcutaneous treatment on alternate days)
Study: 1904892
Drug: Open label
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label drug titration (nonrandomized patients)
Study: 1904892
Drug: Double-blind placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind placebo therapy (control group)
Study: 29171848
Drug: (+)-epicatechin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-epicatechin (30 mg per day for 7 days)
Study: 29171848
Drug: (+)-epicatechin (incremental
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-epicatechin (incremental doses of 10, 30 or 100 mg)
Study: 29171848
Drug: (+)-epicatechin (0.003,
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-epicatechin (0.003, 0.01, 0.03, 0.1 and 0.3 mg kg-1 day-1 for 2 weeks)
Study: 29171848
Drug: +catechin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: +catechin (0.1 mg kg-1 day-1)
Study: 29231495
Drug: Shallow needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shallow needling therapy (at sites 0.2 to 0.3 cun lateral to the acupoints, no qi arrival required)
Study: 29231495
Drug: Shallow needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shallow needling therapy
Study: 25588685
Drug: AEQ >0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEQ >0.4 ng/L/s in patients with paroxysmal AF
Study: 16636540
Drug: Plasma NT-proBNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma NT-proBNP >162.2 pmol/l
Study: 16636540
Drug: Plasma NT-proBNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma NT-proBNP levels in the highest quartile (> or =162.2 pmol/l)
Study: 12559795
Drug: IM high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM high dose hepatitis B virus (HBV) vaccine
Study: 12559795
Drug: IM standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM standard dose HBV vaccine plus granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)
Study: 12559795
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose HBV vaccine plus GM‐CSF
Study: 3318723
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg methylprednisolone infusion
Study: 3318723
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g methylprednisolone infusion
Study: 3318723
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (unspecified alternative therapy)